公开(公告)号：US20230219968A1

公开(公告)日：2023-07-13

申请号：US18176647

申请日：2023-03-01

Applicant: AbbVie Inc.

Inventor： Ayman Allian ,  Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Mathew M. Mulhem ,  Fredrik Lars Nordstrom ,  Ahmed A. Othman ,  Michael J. Rozema ,  Lakshmi Bhagavatula ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ahmad Y. Sheikh ,  Thomas B. Borchardt ,  Ben Klunder

IPC: C07D487/14 ,  A61K9/00 ,  A61K47/12 ,  A61K31/4985 ,  A61K47/38

CPC classification number: C07D487/14 ,  A61K9/0053 ,  A61K47/12 ,  A61K31/4985 ,  A61K47/38 ,  C07B2200/13

Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.